Colin Brown, MD
Gastroenterology · Freehold, NJNPI 1053371203
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,168, 2.6 times the $454 reported in 2019.
Across 234 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$842
- Johnson & Johnson$644
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$515
- Takeda Pharmaceuticals U.S.A., Inc.$498
- Pfizer$296
- QOL Medical, LLC$267
- plus $1K from 17 others
Across 51 payments — averaging $4948.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Braintree Laboratories, Inc.$103K
- Sanofi US Services Inc.$87K
- Bausch Health US, LLC$56K
- Pfizer$4K
- Eli Lilly$2K
What the payments were for
- Speaking & faculty fees$200%
- Grants$200%
- Food & beverage$4,13997%
- Education$722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $842 |
| Johnson & Johnson(2 entities) | 24 | $644 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $515 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $498 |
| Pfizer | 18 | $296 |
| QOL Medical, LLC | 13 | $267 |
| Madrigal Pharmaceuticals | 6 | $233 |
| Bristol Myers Squibb | 9 | $128 |
| Merck | 8 | $115 |
| Braintree Laboratories, Inc. | 7 | $102 |
| Laborie Medical Technologies Corp. | 2 | $90 |
| Ipsen Biopharmaceuticals, Inc | 4 | $80 |
| Ardelyx, Inc. | 4 | $78 |
| Shionogi Inc | 6 | $77 |
| Sanofi | 3 | $65 |
| Boston Scientific | 2 | $39 |
| Novo Nordisk | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$146
- Tremfya$125
- STELARA$125
- LINX Reflux Management System$122
- XIFAXAN$118
How this compares
$4,251 in reported general payments places this provider in the 65th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 33 | $146,283 |
| XifaxanRifaximin | 24 | $50,530 |
| LinzessLinaclotide | 50 | $36,853 |
| ViberziEluxadoline | 11 | $17,074 |
| Mesalamine | 23 | $12,196 |
| Dexlansoprazole DrDexlansoprazole | 28 | $9,391 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 129 | $8,353 |
| Pantoprazole Sodium | 349 | $5,762 |
| CholestyramineCholestyramine (With Sugar) | 63 | $5,254 |
| Balsalazide Disodium | 16 | $3,636 |
| Colesevelam Hcl | 14 | $3,523 |
| Budesonide EcBudesonide | 11 | $2,073 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,878 |
| Omeprazole | 125 | $1,691 |
| Sucralfate | 72 | $1,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Viberzi | $842 | $200,20994 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $515 | $50,53024 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $33 | $1,87811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Freehold
- Vinod RustgiNew Brunswick$431K
- Zamir BrelviNewark$391K
- Adam ElfantMount Laurel$385K
- Devjit NayarHoboken$258K
- Lea ChenNew Brunswick$185K
- Alexander PerelmanWest Orange$160K
- Barry KaufmanEgg Harbor Township$157K
- Anish ShethPrinceton$151K
- Ramesh GuptaFair Lawn$143K
- Sanket PatelVoorhees$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.